All In Biotech

Drug Trial Radar · NCT06476132

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients

Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients: A Randomized, Multicenter, Double Blind, Placebo-Controlled Trial (CTOT-47)

Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

234

Planned (sponsor's estimate)

Start

Mar 12, 2025

Primary completion

May 30, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
NIH
First posted
Jun 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see if taking the study drug, Belumosudil, for 52 weeks in addition to your usual care and medication, will prevent Chronic Lung Allograft Dysfunction (CLAD) in participants who have a lung biopsy that shows evidence of rejection or inflammation to the transplanted lung(s). For this study, biopsies that show evidence of Acute Rejection (AR), Lymphocytic Bronchiolitis (LB), Organizing Pneumonia (OP) or Acute Lung Injury (ALI) are referred to as "Qualifying Biopsies"; patients who had evidence of one or more of these conditions on a recent biopsy are eligible for enrollment in this study. Belumosudil is an investigational drug that blocks a molecule in the body that reduces inflammation and scarring and may play a role in the development and progression of CLAD. Belumosudil is a drug approved by the FDA to treat adults and children 12 years and older with chronic graft-versus-host disease (cGVHD), a condition with some similarities to CLAD. The primary objective it to determine the efficacy of treatment with Belumosudil + maintenance immunosuppression (IS) versus placebo + maintenance IS on preventing the subsequent development of probable or definite CLAD, lung retransplant, or death.

Conditions

  • Lung Transplant

Interventions

  • BelumosudilDrug

    Participants will receive Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.

  • Placebo for BelumosudilDrug

    Participants will receive Placebo for Belumosudil 200 mg daily (increased to 200 mg twice daily in participants receiving concurrent strong CYP3A inducers or PPIs) + maintenance IS for a duration of one year from randomization.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from randomization to the first occurrence of probable or definite CLAD (per ISHLT 2019 standard defined criteria), lung retransplant, or deathTime frame: From randomization until study completion - scheduled assessments: minimum of 1 year, maximum of 3 years

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Los Angeles (Site #: 71123)

    Los Angeles, California · Recruiting

  • Stanford University (Site #: 71141)

    Palo Alto, California · Recruiting

  • Johns Hopkins (Site #: 71119)

    Baltimore, Maryland · Recruiting

  • University of Minnesota (Site 71151)

    Minneapolis, Minnesota · Recruiting

  • Washington University (Site #: 71157)

    St Louis, Missouri · Recruiting

  • NYU Langone Health (Site #: 71177)

    New York, New York · Recruiting

  • Duke University (Site #: 71139)

    Durham, North Carolina · Recruiting

  • Cincinnati Children's Hospital Medical Center (Site #: 71017)

    Cincinnati, Ohio · Recruiting

  • Cleveland Clinic (Site #: 71101)

    Cleveland, Ohio · Recruiting

  • University of Pennsylvania (Site #: 71111)

    Philadelphia, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center (Site #: 71174)

    Nashville, Tennessee · Recruiting

  • University Health Network/Toronto General Hospital (Site #: 71121)

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.